Specialist GP Nikki Vadgama provides some tips to make your next paediatric eczema consult easier. She includes a review of new guidelines, resources, websites and medications for paediatric eczema management
Another COVID-19 drug in the medicine chest
Another COVID-19 drug in the medicine chest
![Undoctored](/sites/default/files/styles/cropped_image_16_7_/public/2021-09/NEW_Undocotred_keyboard.jpg?itok=MkZisK2R)
Health Minister Andrew Little says New Zealanders who contract COVID-19 now have access to six medicines proven to safely prevent the most severe and life-threatening symptoms of the virus.
Andrew Little was in Auckland this afternoon to see the first shipment of molnupiravir, the second oral anti-viral COVID-19 medicine to arrive in the country.
“Anti-virals stop people with mild COVID-19 symptoms from becoming very sick and needing to go to hospital, and because they are pills, they are easy for people to take at home,” Andrew Little said.
New Zealand was one of the first countries to secure access to supplies of molnupiravir. It was approved this month by medicines regulator Medsafe, and the first shipment has just arrived.
“Vaccination is still our first and best line of defence, but it is important to have a range of treatments available for people who contract COVID-19 and are at risk of becoming seriously ill,” Andrew Little said.
“We already have four medicines – Baricitinib, Ronapreve, Remdesivir and Tocilizumab – being used in hospitals, and this month another anti-viral, Paxlovid, started being used to treat people at home.
“Adding molnupiravir into the mix means doctors have got a range of medicines to combat the worst symptoms of COVID-19 and protect people who are immunocompromised or have complex health conditions. It also helps prevent the health system from being overwhelmed,” Andrew Little said.
Another medicine, Evusheld, a prophylactic treatment which can prevent people who can’t have vaccines from getting COVID-19, is awaiting Medsafe approval.
All COVID-19 medicines are funded through the Government’s COVID-19 fund.
Molnupiravir (brand name Lageviro) is a course of four tablets, taken every 12 hours for five days. It will be available to prescribe from early May.
Molnupiravir, like Paxlovid, has strict access criteria, which have been updated to allow more people to be eligible. Immunocompromised people and those with existing health conditions who have tested positive for COVID-19 can contact their GP for an assessment.
More than 800 courses of Paxlovid have been dispensed so far.
More information about COVID-19 treatments, including the access criteria, can be found on the Pharmac website.